BioTime, Inc. (NYSEMKT:BTX) has been given a consensus rating of “Hold” by the six research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $5.33.
A number of research analysts have recently issued reports on the company. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $6.50 target price (up from $6.00) on shares of BioTime in a research note on Monday, June 19th. ValuEngine raised BioTime from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. BidaskClub cut BioTime from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research cut BioTime from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd.
ILLEGAL ACTIVITY WARNING: This story was first reported by BBNS and is the property of of BBNS. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://baseballnewssource.com/markets/biotime-inc-btx-receives-consensus-rating-of-hold-from-brokerages-updated-updated/1314335.html.
In other news, Director Broadwood Partners, L.P. purchased 150,000 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were bought at an average cost of $2.80 per share, for a total transaction of $420,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have acquired 154,000 shares of company stock worth $432,320 over the last 90 days.
Several hedge funds have recently made changes to their positions in BTX. State Street Corp raised its position in BioTime by 9.3% in the fourth quarter. State Street Corp now owns 1,045,826 shares of the biotechnology company’s stock valued at $3,775,000 after buying an additional 89,189 shares during the period. Berson & Corrado Investment Advisors LLC raised its position in BioTime by 83.1% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 61,875 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 28,075 shares during the period. Jane Street Group LLC raised its position in BioTime by 19.4% in the first quarter. Jane Street Group LLC now owns 92,685 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 15,080 shares during the period. Nationwide Fund Advisors raised its position in BioTime by 2.2% in the first quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 939 shares during the period. Finally, Russell Investments Group Ltd. raised its position in BioTime by 306.7% in the first quarter. Russell Investments Group Ltd. now owns 96,303 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 72,624 shares during the period.
Shares of BioTime (NYSEMKT BTX) traded down 1.42% during midday trading on Monday, hitting $2.77. 490,716 shares of the stock were exchanged. The firm has a market capitalization of $307.12 million, a price-to-earnings ratio of 4.66 and a beta of 1.37. BioTime has a 1-year low of $2.50 and a 1-year high of $4.01. The stock’s 50-day moving average price is $2.99 and its 200-day moving average price is $3.15.
BioTime Company Profile
BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.
Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with our FREE daily email newsletter.